ES2159209T3 - Uso de acido 11-(3-dimetilaminopropiliden)-6,11-dihidrodibenz(b,e)oxepin-2-acetico y de sus sales farmaceuticamente aceptables para la fabricacion de un medicamento para el tratamiento de trastornos oftalmicos no alergicos y para la prevencion de neovascularizacion ocular. - Google Patents

Uso de acido 11-(3-dimetilaminopropiliden)-6,11-dihidrodibenz(b,e)oxepin-2-acetico y de sus sales farmaceuticamente aceptables para la fabricacion de un medicamento para el tratamiento de trastornos oftalmicos no alergicos y para la prevencion de neovascularizacion ocular.

Info

Publication number
ES2159209T3
ES2159209T3 ES99928600T ES99928600T ES2159209T3 ES 2159209 T3 ES2159209 T3 ES 2159209T3 ES 99928600 T ES99928600 T ES 99928600T ES 99928600 T ES99928600 T ES 99928600T ES 2159209 T3 ES2159209 T3 ES 2159209T3
Authority
ES
Spain
Prior art keywords
oxepin
administration
manufacture
dimethylamopropiliden
dihidrodibenz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99928600T
Other languages
English (en)
Inventor
John M Yanni
Daniel A Gamache
Lori K Weimer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of ES2159209T3 publication Critical patent/ES2159209T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El uso del ácido 11-(3-dimetilamino-propilidén)-6,11-dihidrodibenz[b,e]oxepin-2-acético, o una sal suya farmacológicamente aceptable, en la fabricación de un medicamento para la administración en el ojo para tratar o impedir la neovascularización ocular y los trastornos inflamatorios oftálmicos, no alérgicos, que implican la liberación de citoquina desde las células oculares humanas.
ES99928600T 1998-07-14 1999-06-15 Uso de acido 11-(3-dimetilaminopropiliden)-6,11-dihidrodibenz(b,e)oxepin-2-acetico y de sus sales farmaceuticamente aceptables para la fabricacion de un medicamento para el tratamiento de trastornos oftalmicos no alergicos y para la prevencion de neovascularizacion ocular. Expired - Lifetime ES2159209T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9276298P 1998-07-14 1998-07-14

Publications (1)

Publication Number Publication Date
ES2159209T3 true ES2159209T3 (es) 2001-09-16

Family

ID=22235027

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99928600T Expired - Lifetime ES2159209T3 (es) 1998-07-14 1999-06-15 Uso de acido 11-(3-dimetilaminopropiliden)-6,11-dihidrodibenz(b,e)oxepin-2-acetico y de sus sales farmaceuticamente aceptables para la fabricacion de un medicamento para el tratamiento de trastornos oftalmicos no alergicos y para la prevencion de neovascularizacion ocular.

Country Status (18)

Country Link
EP (1) EP1037627B1 (es)
JP (1) JP2002520355A (es)
KR (1) KR100598723B1 (es)
CN (1) CN1114401C (es)
AR (1) AR019916A1 (es)
AT (1) ATE203668T1 (es)
AU (1) AU742237B2 (es)
BR (1) BR9906772A (es)
CA (1) CA2306393C (es)
DE (1) DE69900207T2 (es)
DK (1) DK1037627T3 (es)
ES (1) ES2159209T3 (es)
GR (1) GR3036422T3 (es)
HK (1) HK1030362A1 (es)
PT (1) PT1037627E (es)
TW (1) TW561046B (es)
WO (1) WO2000003705A1 (es)
ZA (1) ZA200001593B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213001T3 (es) * 1999-06-18 2004-08-16 Alcon Manufacturing Ltd. Metodo para seleccionar la concentracion de un farmaco antihistaminico anfipatico mediante determinacion del valor de actividad superficial del farmaco.
WO2002034246A2 (en) * 2000-10-23 2002-05-02 Alcon, Inc. Use of hydroperoxyeicosatetraenoic acid derivatives following refractive surgery
MXPA03010632A (es) 2001-05-21 2004-03-09 Alcon Inc Uso de inhibidores de nf-kb para tratar trastornos de resequedad de ojos.
DK1392355T3 (da) 2001-05-21 2007-04-30 Alcon Inc Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
AU2003235454A1 (en) 2002-06-14 2003-12-31 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
US20040072809A1 (en) 2002-07-30 2004-04-15 Omeros Corporation Ophthalmologic irrigation solutions and method
AU2003278727A1 (en) * 2002-09-20 2004-04-08 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US7235556B2 (en) 2003-04-16 2007-06-26 Alcon, Inc. Methods of treating dry eye disorders
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7923471B2 (en) 2004-05-14 2011-04-12 Alcon, Inc. Method of treating dry eye disorders and uveitis
EP3470108A1 (en) 2004-07-02 2019-04-17 Mati Therapeutics Inc. Treatment medium delivery device for delivery of treatment media to the eye
US7223737B1 (en) 2004-08-13 2007-05-29 Alcon, Inc. Method of treating dry eye disorders using glycosides
DK2444079T3 (en) * 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
EP2010143B1 (en) 2006-03-17 2015-08-12 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
BRPI0709672B8 (pt) 2006-03-31 2021-06-22 3088922 Inc implante ocular insersível em um lúmen ocular e método de distribuição de um agente terapêutico a um olho
AU2008300022A1 (en) 2007-09-07 2009-03-19 Qlt Inc. Lacrimal implant detection
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
CA2774054A1 (en) 2009-11-06 2011-05-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CN109311976A (zh) 2016-06-20 2019-02-05 诺华股份有限公司 使用TNFα拮抗剂治疗干眼症的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6310784A (ja) * 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
JPH02138215A (ja) * 1988-08-05 1990-05-28 Dai Ichi Seiyaku Co Ltd 抗アレルギー・抗炎症剤
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
JP3453152B2 (ja) * 1992-04-06 2003-10-06 格 冨山 抗炎症点眼剤
FR2701948B1 (fr) * 1993-02-22 1996-07-26 Exsymol Sa Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires.
ATE241359T1 (de) * 1993-03-26 2003-06-15 Beth Israel Hospital Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind
FR2711990B1 (fr) * 1993-11-05 1995-12-08 Exsymol Sa Produit pseudodipeptide possédant un groupement imidazole, et applications thérapeutiques, cosmétologiques et agroalimentaires.
JP2852607B2 (ja) * 1994-06-10 1999-02-03 雪印乳業株式会社 ドライアイ治療剤
US5641805A (en) * 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
JPH1067684A (ja) * 1996-06-17 1998-03-10 Mitsubishi Chem Corp 涙液分泌促進剤
EP0944395A1 (en) * 1996-11-19 1999-09-29 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye

Also Published As

Publication number Publication date
DE69900207T2 (de) 2001-11-22
BR9906772A (pt) 2000-09-26
AR019916A1 (es) 2002-03-27
ZA200001593B (en) 2000-10-25
JP2002520355A (ja) 2002-07-09
GR3036422T3 (en) 2001-11-30
KR20010024508A (ko) 2001-03-26
DE69900207D1 (de) 2001-09-06
TW561046B (en) 2003-11-11
AU4563499A (en) 2000-02-07
ATE203668T1 (de) 2001-08-15
WO2000003705A1 (en) 2000-01-27
CN1275078A (zh) 2000-11-29
EP1037627A1 (en) 2000-09-27
KR100598723B1 (ko) 2006-07-11
CA2306393A1 (en) 2000-01-27
EP1037627B1 (en) 2001-08-01
HK1030362A1 (en) 2001-05-04
DK1037627T3 (da) 2001-10-01
CN1114401C (zh) 2003-07-16
AU742237B2 (en) 2001-12-20
PT1037627E (pt) 2001-11-30
CA2306393C (en) 2008-12-23

Similar Documents

Publication Publication Date Title
ES2159209T3 (es) Uso de acido 11-(3-dimetilaminopropiliden)-6,11-dihidrodibenz(b,e)oxepin-2-acetico y de sus sales farmaceuticamente aceptables para la fabricacion de un medicamento para el tratamiento de trastornos oftalmicos no alergicos y para la prevencion de neovascularizacion ocular.
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
AR048646A1 (es) Implante intraocular o intravitreo biodegradable que comprende un inhibidor de tirosina quinasa y un polimero biodegradable, metodo para producirlo y medicamento correspondiente
TW200505402A (en) Ophthalmic drug delivery device
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
BRPI0312128B8 (pt) formulação farmacêutica compreendendo azelastina e éster de fluticasona
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
DK0799044T3 (da) Topiske oftalmologiske formuleringer indeholdende olopatidin til behandling af allergiske øjensygdomme
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
GEP20033090B (en) Derivatives of Acyl-Piperazinil-Pyrimidins, Preparation, Method for Their Preparation and Their Application
HUP0202671A2 (hu) Ketotifen optikailag aktív izomerei és aktív metabolitjai
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
EP1440689A3 (en) Treatment of neurotic disorders
AR004378A1 (es) Utilizacion de los derivados de 1-{4-(4-aril(o heteroaril)-1-piperazinil)- butil}-1h-azol para la preparacion de un medicamento destinado al tratamientode los trastornos obsesivo-compulsivos, la apnea del sueno, las disfunciones sexuales, la emesis y el mareo en los mamiferos, incluido el hombre.
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
ES2109752T3 (es) Medicamento para tratamiento terapeutico y profilactico de enfermedades causadas por hiperplasia de las celulas de los musculos lisos.
IT1276031B1 (it) Composizione farmaceutica per il trattamento delle malattie autoimmuni
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
AR007369A1 (es) El uso de derivados carboxilados y un medicamento que contiene uno o mas de dichos derivados

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1037627

Country of ref document: ES